JP2022512736A5 - - Google Patents

Info

Publication number
JP2022512736A5
JP2022512736A5 JP2021521145A JP2021521145A JP2022512736A5 JP 2022512736 A5 JP2022512736 A5 JP 2022512736A5 JP 2021521145 A JP2021521145 A JP 2021521145A JP 2021521145 A JP2021521145 A JP 2021521145A JP 2022512736 A5 JP2022512736 A5 JP 2022512736A5
Authority
JP
Japan
Prior art keywords
compound
compound according
mol
deuterium
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521145A
Other languages
English (en)
Japanese (ja)
Other versions
JP7603199B2 (ja
JP2022512736A (ja
Filing date
Publication date
Priority claimed from GBGB1816998.7A external-priority patent/GB201816998D0/en
Priority claimed from GBGB1909695.7A external-priority patent/GB201909695D0/en
Application filed filed Critical
Priority claimed from PCT/EP2019/078250 external-priority patent/WO2020079165A1/en
Publication of JP2022512736A publication Critical patent/JP2022512736A/ja
Publication of JP2022512736A5 publication Critical patent/JP2022512736A5/ja
Priority to JP2024107578A priority Critical patent/JP2024150488A/ja
Application granted granted Critical
Publication of JP7603199B2 publication Critical patent/JP7603199B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521145A 2018-10-18 2019-10-17 重水素を含有する化合物 Active JP7603199B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024107578A JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1816998.7A GB201816998D0 (en) 2018-10-18 2018-10-18 Compounds
GB1816998.7 2018-10-18
GBGB1909695.7A GB201909695D0 (en) 2019-07-05 2019-07-05 Compounds
GB1909695.7 2019-07-05
PCT/EP2019/078250 WO2020079165A1 (en) 2018-10-18 2019-10-17 Compounds containing deuterium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024107578A Division JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Publications (3)

Publication Number Publication Date
JP2022512736A JP2022512736A (ja) 2022-02-07
JP2022512736A5 true JP2022512736A5 (enExample) 2022-10-18
JP7603199B2 JP7603199B2 (ja) 2024-12-20

Family

ID=68290247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521145A Active JP7603199B2 (ja) 2018-10-18 2019-10-17 重水素を含有する化合物
JP2024107578A Pending JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024107578A Pending JP2024150488A (ja) 2018-10-18 2024-07-03 重水素を含有する化合物

Country Status (19)

Country Link
US (2) US12152087B2 (enExample)
EP (1) EP3866931B1 (enExample)
JP (2) JP7603199B2 (enExample)
KR (1) KR102848971B1 (enExample)
CN (1) CN112930214B (enExample)
AU (1) AU2019362389B2 (enExample)
BR (1) BR112021007060A2 (enExample)
CA (1) CA3116198A1 (enExample)
DK (1) DK3866931T3 (enExample)
ES (1) ES2942468T3 (enExample)
FI (1) FI3866931T3 (enExample)
HU (1) HUE061801T2 (enExample)
IL (1) IL282231B2 (enExample)
MA (1) MA53904A (enExample)
MX (1) MX2021004474A (enExample)
PL (1) PL3866931T3 (enExample)
SG (1) SG11202103726RA (enExample)
WO (1) WO2020079165A1 (enExample)
ZA (1) ZA202102492B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
ES3034388T3 (en) * 2021-06-01 2025-08-18 Synthon Bv Process for making melflufen or a salt thereof
JP2024524552A (ja) 2021-07-08 2024-07-05 オンコペプティデス エービー 多発性骨髄腫の治療に使用するためのメルフルフェン
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations
WO2026057823A1 (en) * 2024-09-13 2026-03-19 Oncopeptides Ab Bis-chloroethylamino derivatives for treating leukemia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
CA2972242A1 (en) 2008-09-18 2010-04-22 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP3351247A1 (en) 2010-06-01 2018-07-25 Auspex Pharmaceutical, Inc. Benzoquinolone inhibitors of vmat2
DK2701720T3 (en) * 2011-04-28 2017-10-09 Oncopeptides Ab Lyophilized preparation with cytotoxic dipeptides
EP4345100A3 (en) 2012-09-18 2024-04-10 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
SMT202000058T1 (it) * 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
JP2016506957A (ja) 2013-01-31 2016-03-07 オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. Vmat2のベンゾキノロン阻害剤
ES2901752T3 (es) * 2013-02-05 2022-03-23 Teva Pharmaceuticals Int Gmbh Derivados de catecolamina enriquecidos con deuterio asimétrico de posición específica y medicamentos que comprenden dichos compuestos
WO2015084622A1 (en) 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
CN110229159B (zh) 2013-12-18 2021-08-24 康塞特医药品有限公司 卢索替尼的氘代衍生物
AU2016229949B2 (en) 2015-03-06 2021-04-08 Auspex Pharmaceuticals Llc Methods for the treatment of abnormal involuntary movement disorders
GB201507903D0 (en) 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens

Similar Documents

Publication Publication Date Title
JP2022512736A5 (enExample)
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
CN113784970A (zh) Erk抑制剂及其应用
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
EA202092169A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2
JP2005523922A5 (enExample)
JP2019014758A5 (enExample)
JP2015537020A5 (enExample)
JP2013525318A5 (enExample)
JP2009504763A5 (enExample)
JP2015509535A5 (enExample)
RU2009102278A (ru) Модуляторы рецептора s1p для лечения рассеянного склероза
JP2013544276A5 (enExample)
CN113784963A (zh) 用作ret激酶抑制剂的化合物及其应用
JP2017530983A5 (enExample)
JP2015512413A5 (enExample)
JP2014505017A5 (enExample)
JP2022537140A5 (enExample)
RU2016136193A (ru) Аминокарбонилкарбаматные соединения
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
JP2017512211A5 (enExample)
JP2020111571A5 (enExample)
CA3155875A1 (en) BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE
JP2015504917A5 (enExample)
JP2022544536A5 (enExample)